Research & Clinical Studies

About Our Research & Clinical Studies

Dedicated researchers at Jersey Shore University Medical Center are working to provide the most innovative technologies and treatment options to patients.

Learn about the full range of cardiac clinical trials Jersey Shore is currently offering.

AngelMed Guardian® ALERTS Clinical Study

Jersey Shore University Medical Center is proud to be the first medical center in the New York / New Jersey Metropolitan area to participate in the ALERTS Pivotal US clinical trial for the AngelMed Guardian implantable cardiac monitor and alert system. The trial is designed to test the efficacy of a device that may significantly reduce time to treatment and thus may decrease heart muscle damage and improve survival rates related to major cardiac events.

Read more about the first patient implanted with this revolutionary device

The AngelMed Guardian device is a pacemaker-like device that is surgically implanted in a patient's chest, and detects, analyzes, and records crucial heart signal data, vibrating to alert the patient of a cardiac event.

According to the American Heart Association, one in every five deaths in the United States is attributable to coronary heart disease. In addition, 50 percent of heart-attack fatalities occur within one hour of the onset of symptoms and occur before the patient even reaches the hospital. With the AngelMed device, patients have the potential of being warned hours, or even days, before heart attack symptoms occur. 

The system has received Food and Drug Administration clearance for clinical trials, but is not approved for general use in the United States yet. Marcia Makoviecki, representative of Angel Medical Systems, the Shrewsbury, New Jersey-based company behind the product, indicates that the system has already been approved for commercial use in Brazil. 

To participate in the ALERTS study, patients must meet the guidelines below.

Patients must meet at least one of the following criteria:

• Diabetes (Type I or Type II)
• Compromised renal function
• TIMI Risk Score ? 3

and all of the following criteria:

• Has presented with a high-risk acute coronary syndrome within the past 6 months
  or
• Undergone or is scheduled for CABG within 6 months of implantation
• Has already undergone coronary angiography and revascularization
• Lives within 60 minutes by EMS to Jersey Shore University Medical Center
• Is at least 21 years of age

If a woman, must test negative for pregnancy or be:

• Post-menopausal or amenorrheic during the past year
• Surgically sterilized
• Using an effective contraceptive method

For more information, or to participate in the ALERTS study, please contact Jersey Shore University Medical Center Office of Clinical Research at 732-776-2953.